<SEC-DOCUMENT>0001102624-11-000292.txt : 20110516
<SEC-HEADER>0001102624-11-000292.hdr.sgml : 20110516
<ACCEPTANCE-DATETIME>20110516131744
ACCESSION NUMBER:		0001102624-11-000292
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110516
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110516
DATE AS OF CHANGE:		20110516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		11845089

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: May       16, 2011</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>207-878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On May 16, 2011 ImmuCell Corporation (the "Company") issued a press release announcing financial results for the three-month period ended March 31, 2011.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br />
<br>

<p>
<b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated May       16, 2011</a></b>
<br>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table border="0" width="100%">
<tr>
<td width="50%" valign=top>
Dated: May       16, 2011<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated May       16, 2011</td>
</tr>
</table>
</center>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for First Quarter of 2011 </b>
<p>PORTLAND, ME -- (Marketwire - May       16, 2011) -  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the quarter ended March 31,
2011.
</p>
<p>
For the three-month period ended March 31, 2011, product sales increased by
19%, or $244,000, to $1,556,000 in comparison to the same period in 2010.
For the twelve-month period ended March 31, 2011, product sales increased
by 6%.
</p>
<p>
"A 21% increase in sales of First Defense&#174; during the first quarter of
2011 over the first quarter of 2010 demonstrates a return on our increased
investment in sales and marketing," commented Michael F. Brigham, President
and CEO.  "This growth in our commercial business is important to us while
we advance towards the completion of the development of Mast Out&#174;."
</p>
<p>
The loss before income taxes was $31,000 during the three-month period
ended March 31, 2011 in comparison to a loss before income taxes of $65,000
during the same period in 2010.   The net loss was $23,000, or $0.01 per
share, during the three-month period ended March 31, 2011 in comparison to
a net loss of $53,000, or $0.02 per share, during the same period in 2010.
</p>
<p>
Cash, cash equivalents and short-term investments increased by 15%, or
$683,000, to $5,309,000 at March 31, 2011 as compared to $4,626,000 at
December 31, 2010.  Stockholders' equity decreased by less than 1%, or
$14,000, to $9,269,000 at March 31, 2011 as compared to $9,282,000 at
December 31, 2010.  The Company had 2,974,000 shares of common stock
outstanding as of March 31, 2011.
</p>
<p>
<pre>
                                                        (Unaudited)
                                                    Three-Month Periods
                                                       Ended March 31,
                                                  ------------------------
(In thousands, except per share amounts)              2011         2010
                                                  -----------  ------------

Product sales                                     $     1,556  $      1,312
Cost of goods sold                                        687           573
                                                  -----------  ------------
Gross margin                                              869           739

Product development expenses                              472           405
Sales, marketing and administrative expenses              413           408
                                                  -----------  ------------
Other operating expenses                                  885           813
                                                  -----------  ------------

NET OPERATING LOSS                                         16            74

Other (expenses) revenues, net                            (15)           10
                                                  -----------  ------------

LOSS BEFORE INCOME TAXES                                   31            64

Income tax benefit                                          8            11
                                                  -----------  ------------

NET LOSS                                          $        23  $         53
                                                  ===========  ============

Weighted average common shares outstanding:
Basic                                                   2,974         2,971
Diluted                                                 2,974         2,971

NET LOSS PER SHARE:
Basic                                             $      0.01  $       0.02
Diluted                                           $      0.01  $       0.02




                                             At March 31,   At December 31,
                                                 2011            2010
                                            --------------- ---------------

Cash, cash equivalents and short-term
 investments                                $         5,309 $         4,626
Total assets                                         11,409          10,751
Net working capital                                   6,881           6,441
Stockholders' equity                        $         9,269 $         9,282

</pre>
</p>
<p>
About ImmuCell:
</p>
<p>
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create
scientifically-proven and practical products that result in a measurable
economic impact on animal health and productivity in the dairy and beef
industries.  Press releases and other information about the Company are
available at our
web-site, (http://www.immucell.com).

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
